Monitor for OCU400 Phase 3 topline data in 1H 2027 and OCU410ST topline data in 2027. The Bahamas EAP revenue ramp and any partnership milestone triggers are key near-term catalysts. No financial results or guidance were provided in this filing.
Price Chart
Executive Summary
Ocugen posted an October 2026 corporate presentation on its website, providing a pipeline update across three gene therapy programs (OCU400 for retinitis pigmentosa, OCU410ST for Stargardt disease, OCU410 for geographic atrophy). The presentation highlights Phase 3 enrollment completion for OCU400 and OCU410ST, positive Phase 2 data for OCU410 showing a 31% lesion size reduction, and a new Early Access Program in the Bahamas for OCU400 that could generate revenue of $1-2M per patient. No new financial results or guidance were provided.
Key Facts
- OCU400 Phase 3 liMeliGhT trial enrolled 140 patients (largest orphan gene therapy trial for RP); topline data expected 1H 2027, BLA filing target 2Q 2027
- OCU410ST Phase 2/3 GARDian3 trial enrollment completed; topline data and BLA submission targeted for 2027
- OCU410 Phase 3 ArMaDa trial initiated 3Q 2026 with 237 patients; Phase 2 data showed 31% lesion size reduction vs control at 12 months (p<0.05)
- Bahamas regulatory agency (LARTA) granted provisional approval for OCU400 under an Early Access Program; Ocugen expects to generate revenue of potentially $1-2M per patient
- Kwangdong OCU400 deal includes potential sales milestones up to $180M+ and 25% royalties; Roots Pharmaceutical deal includes up to $255M milestones and 22% royalties
- OCU400 showed durable LLVA treatment effect through 3 years: mean +8.9 letters vs untreated eyes; no SAEs related to OCU400
- OCU410 showed no OCU410-related SAEs or AESIs reported to date
Financial Impact
No financial results reported. Potential revenue from Bahamas EAP at $1-2M per patient; partnership milestones up to $180M (Kwangdong) and $255M (Roots) are contingent and not yet earned.
Risk Factors
- Clinical trial failure: Phase 3 topline data for OCU400 and OCU410ST are pending and could miss endpoints
- Regulatory risk: Bahamas EAP is provisional and full approval is pending site readiness within 90 days
- Dilution risk: As a pre-revenue biotech, Ocugen may need to raise capital to fund operations and trials
- Competition: Approved GA therapies (SYFOVRE, IZERVAY) have >$1B combined annual sales; OCU410 must demonstrate superior efficacy and convenience
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-115970 |
| Document: tm2627592d2_8k.htm | 0001104659-26-115970 |
| Document: 0001104659-26-115970-index-headers.html | 0001104659-26-115970 |
| Document: 0001104659-26-115970-index.html | 0001104659-26-115970 |
| Document: 0001104659-26-115970.txt | 0001104659-26-115970 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 12d ago | 8-K | $0.8137 $0.7803 | ▼ −4.10% | ▼ −3.00% | $0.7574 (−6.92%) |
Oct 14, 2026 12d ago | 8-K | $0.8137 $0.7803 | ▼ −4.10% | ▼ −3.00% | $0.7574 (−6.92%) |
Oct 9, 2026 18d ago | 144 | $0.9472 $0.8854 | ▼ −6.52% | ▼ −6.51% | $0.7574 (−20.04%) |
Sep 1, 2026 8w ago | Press Release | $1.33 $1.32 | ▼ −0.75% | ▼ −1.20% | $0.7574 (−43.05%) |
Jul 13, 2026 15w ago | 8-K | $1.41 $1.43 | ▲ +1.42% | ▲ +1.06% | $0.7574 (−46.28%) |
Jun 11, 2026 19w ago | 8-K | $1.21 $1.22 | ▲ +0.83% | ▼ −0.94% | $0.7574 (−37.40%) |
Jun 11, 2026 19w ago | Institutional Cluster | $1.22 $1.21 | ▼ −0.82% | ▼ −1.36% | $0.7574 (−37.92%) |
May 5, 2026 25w ago | 8-K | $1.49 $1.46 | ▼ −2.35% | ▼ −3.73% | $0.7574 (−49.17%) |
May 5, 2026 25w ago | Press Release | $1.49 $1.46 | ▼ −2.35% | ▼ −3.73% | $0.7574 (−49.17%) |
May 5, 2026 25w ago | Press Release | $1.49 $1.46 | ▲ +2.35% | ▲ +3.73% | $0.7574 (+49.17%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers